By elucidating the mechanistic link between SYNGAP1 and the Wnt/β-Catenin pathway, our research provides a novel avenue for developing targeted therapies against this signaling axis, thus opening up new avenues for READ treatment. Here, SYNGAP1 is linked to reading.